Unlike the discovery phase, ELISA validation showed a significant enrichment of FCGR3A in PPMS patients compared to HC (Padj = 0.034; FC = 1.55; Cliff’s δ = 0.49), indicating a large effect size. The gene discussed is FCGR3A; the disease is primary progressive multiple sclerosis.